Segui
Elena Criscuolo
Elena Criscuolo
Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University
Email verificata su hsr.it - Home page
Titolo
Citata da
Citata da
Anno
Mendelian randomization
E Birney
Cold Spring Harbor perspectives in medicine, a041302, 2021
2142021
The interferon landscape along the respiratory tract impacts the severity of COVID-19
B Sposito, A Broggi, L Pandolfi, S Crotta, N Clementi, R Ferrarese, S Sisti, ...
Cell 184 (19), 4953-4968. e16, 2021
1932021
Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines
E Criscuolo, V Caputo, RA Diotti, GA Sautto, GA Kirchenbaum, ...
Journal of immunology research 2019, 2019
1142019
Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro
N Clementi, C Scagnolari, A D’Amore, F Palombi, E Criscuolo, F Frasca, ...
Pharmacological research 163, 105255, 2021
1132021
Viral respiratory pathogens and lung injury
N Clementi, S Ghosh, M De Santis, M Castelli, E Criscuolo, I Zanoni, ...
Clinical microbiology reviews 34 (3), 10.1128/cmr. 00103-20, 2021
1002021
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
E Criscuolo, RA Diotti, R Ferrarese, C Alippi, G Viscardi, C Signorelli, ...
Emerging Microbes & Infections 10 (1), 206-209, 2021
882021
Bacteriophages and Their Immunological Applications against Infectious Threats
C Elena, S Spadini, J Lamanna, M Ferro, R Burioni
Journal of Immunology Research 2017, 13, 2017
762017
Interferon-β-1a inhibition of severe acute respiratory syndrome–coronavirus 2 in vitro when administered after virus infection
N Clementi, R Ferrarese, E Criscuolo, RA Diotti, M Castelli, C Scagnolari, ...
The Journal of infectious diseases 222 (5), 722-725, 2020
752020
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
M Severa, RA Diotti, MP Etna, F Rizzo, S Fiore, D Ricci, M Iannetta, ...
PLoS pathogens 17 (9), e1009878, 2021
662021
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
A Conforti, E Marra, F Palombo, G Roscilli, M Ravà, V Fumagalli, A Muzi, ...
Molecular Therapy 30 (1), 311-326, 2022
56*2022
Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects
E Criscuolo, RA Diotti, M Strollo, S Rolla, A Ambrosi, M Locatelli, ...
Journal of medical virology 93 (4), 2160-2167, 2021
53*2021
Unconventional CD147‐dependent platelet activation elicited by SARS‐CoV‐2 in COVID‐19
N Maugeri, R De Lorenzo, N Clementi, RA Diotti, E Criscuolo, C Godino, ...
Journal of Thrombosis and Haemostasis 20 (2), 434-448, 2022
482022
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by …
M Castelli, F Cappelletti, RA Diotti, G Sautto, E Criscuolo, M Dal Peraro, ...
Journal of Immunology Research 2013, 2013
402013
Neutralization interfering antibodies: a “novel” example of humoral immune dysfunction facilitating viral escape?
M Nicasio, G Sautto, N Clementi, RA Diotti, E Criscuolo, M Castelli, ...
Viruses 4 (9), 1731-1752, 2012
302012
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects
D Ferrari, N Clementi, SM Spanò, S Albitar-Nehme, S Ranno, ...
Clinica Chimica Acta 522, 144-151, 2021
292021
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
RA Diotti, A Nakanishi, N Clementi, N Mancini, E Criscuolo, L Solforosi, ...
Journal of Immunology Research 2013, 2013
272013
Antibody titer kinetics and SARS-CoV-2 infections six months after administration with the BNT162b2 vaccine
D Ferrari, N Clementi, E Criscuolo, A Ambrosi, F Corea, C Di Resta, ...
Vaccines 9 (11), 1357, 2021
262021
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis.
N Clementi, E Criscuolo, M Castelli, M Clementi
Microbiologica-Quarterly Journal of Microbiological Sciences 35 (4), 399, 2012
262012
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
N Clementi, E Criscuolo, RA Diotti, R Ferrarese, M Castelli, L Dagna, ...
Frontiers in microbiology 11, 1704, 2020
202020
Cell-to-cell spread blocking activity is extremely limited in the sera of herpes simplex virus 1 (HSV-1)-and HSV-2-infected subjects
E Criscuolo, M Castelli, RA Diotti, V Amato, R Burioni, M Clementi, ...
Journal of Virology 93 (11), 10.1128/jvi. 00070-19, 2019
202019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20